Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TNXPBullishCorporate Developmentsnews

High materiality9/10

Tonix Expands TONMYA Patient Access, Stock Rallies Over 5%

May 6, 2026, 9:31 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The agreement signals strong potential for revenue growth, akin to past instances where expanding access led to stock surges, indicating a bullish sentiment.

AI summary

What happened, with direct paths to the underlying reporting

Tonix Pharmaceuticals has secured an agreement increasing access to its fibromyalgia treatment, TONMYA, for approximately 35 million people. This pivotal move could drive significant revenue growth as the company aims for further coverage expansions, positively impacting TNXP stock value.

Tonix entered an agreement covering 35 million U.S. lives.
Agreement expands access to TONMYA, the first new fibromyalgia treatment in 15 years.
TONMYA is also covered by Medicaid in 38 states.
Shares trade 5.93% higher, reflecting positive market sentiment.
Company plans to pursue additional coverage opportunities.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Tonix Expands TONMYA Patient Access, Stock Rallies Over 5%

Tonix gains from second GPO coverage expansion for TONMYA, 52M lives

Tonix Pharmaceuticals Reports Positive Early Adoption of TONMYA and Solid Financials

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition